American International Group Inc. Raises Stock Holdings in EQRx, Inc. (NASDAQ:EQRX)

American International Group Inc. raised its stake in shares of EQRx, Inc. (NASDAQ:EQRX) by 58.3% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 153,584 shares of the company’s stock after buying an additional 56,559 shares during the period. American International Group Inc.’s holdings in EQRx were worth $286,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of EQRX. Bank of New York Mellon Corp acquired a new stake in shares of EQRx during the 1st quarter valued at about $415,000. Citigroup Inc. acquired a new stake in EQRx in the 1st quarter worth about $116,000. BlackRock Inc. acquired a new stake in EQRx in the 1st quarter worth about $13,021,000. Vanguard Group Inc. acquired a new stake in EQRx in the 1st quarter worth about $12,131,000. Finally, Penserra Capital Management LLC boosted its holdings in EQRx by 69.8% in the 1st quarter. Penserra Capital Management LLC now owns 20,588 shares of the company’s stock worth $85,000 after buying an additional 8,462 shares during the last quarter. 72.33% of the stock is currently owned by institutional investors and hedge funds.

EQRx Trading Down 2.1 %

EQRX stock opened at $2.34 on Monday. EQRx, Inc. has a 12-month low of $1.58 and a 12-month high of $5.55. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -4.25 and a beta of 0.48. The business’s 50-day moving average is $2.26 and its 200 day moving average is $2.07.

EQRx Profile

EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer.